Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of polyethylene glycol (PEG), ascorbic acid (vitamin C), and simethicone. It is primarily used for bowel preparation before colonoscopy. Polyethylene glycol acts as an osmotic laxative by retaining water in the stool, resulting in softer stools and promoting bowel movements. Ascorbic acid enhances the laxative effect through its osmotic properties and also helps reduce the required volume of PEG solution. Simethicone is an antifoaming agent that reduces gas bubbles in the gastrointestinal tract, improving mucosal visibility during colonoscopy and reducing patient discomfort such as bloating or abdominal fullness[1][2][3][4]. The combination has been shown to provide superior bowel cleansing efficacy compared to PEG-ascorbic acid alone, with better patient tolerability and improved endoscopist satisfaction[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + ascorbic acid + simethicone.